Stockscreener 앱 받기
8.05
12.75%
0.91
전일 마감가:
$7.14
열려 있는:
$7.14
하루 거래량:
3.04M
Relative Volume:
2.34
시가총액:
$601.19M
수익:
-
순이익/손실:
$-27.03M
주가수익비율:
-14.38
EPS:
-0.56
순현금흐름:
$-23.97M
1주 성능:
+18.56%
1개월 성능:
+1.39%
6개월 성능:
+89.41%
1년 성능:
+70.19%
1일 변동 폭
$7.0714
$8.17
1주일 범위
$6.39
$8.17
52주 변동 폭
$2.54
$9.60
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
863 MITTEN ROAD, BURLINGAME, CA
CRVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
8.05 | 533.23M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals to Report Phase 1 Trial Results on January 20, 2026 - Intellectia AI
Corvus Pharmaceuticals to Host Conference Call on Phase 1 Trial Results of Soquelitinib for Atopic Dermatitis - Quiver Quantitative
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
New atopic dermatitis drug trial results to be shared in Jan. 20 webcast - Stock Titan
Profit Recap: What analysts say about Corvus Pharmaceuticals Inc stock2025 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 7.1%Still a Buy? - MarketBeat
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% - Yahoo Finance
Panic Selling: Will Corvus Pharmaceuticals Inc outperform during market ralliesBull Run & Safe Capital Growth Tips - baoquankhu1.vn
Will Corvus Pharmaceuticals Inc. stock split attract more investors2025 Bull vs Bear & AI Optimized Trading Strategy Guides - Улправда
Will Corvus Pharmaceuticals Inc. stock gain from lower inflation2025 Retail Activity & Step-by-Step Swing Trade Plans - Улправда
Is Corvus Pharmaceuticals Inc. stock ready for breakoutIndex Update & Risk Controlled Swing Alerts - Улправда
Corvus Pharmaceuticals to announce atopic dermatitis trial results in January By Investing.com - Investing.com Nigeria
Sectors Review: Can Corvus Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - Улправда
Will Corvus Pharmaceuticals Inc. stock outperform international peers2025 AllTime Highs & AI Powered Market Entry Strategies - Улправда
Is Corvus Pharmaceuticals Inc. stock a good choice for value investorsJuly 2025 Update & Accurate Intraday Trade Tips - Улправда
How supply chain issues affect Corvus Pharmaceuticals Inc. stockMarket Movement Recap & Capital Efficiency Focused Strategies - Улправда
Should I hold or sell Corvus Pharmaceuticals Inc. stock in 20252025 Key Lessons & Reliable Entry Point Trade Alerts - Улправда
Hedge Fund Moves: Is Corvus Pharmaceuticals Inc stock ready for breakout2025 Winners & Losers & Technical Pattern Alert System - Bộ Nội Vụ
Can Corvus Pharmaceuticals Inc. stock beat analyst upgradesMarket Volume Summary & Technical Buy Zone Confirmation - Улправда
Both Retail Investors Who Control a Good Portion of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Along With Institutions Must Be Dismayed After Last Week's 9.3% Decrease - 富途牛牛
Both retail investors who control a good portion of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) along with institutions must be dismayed after last week's 9.3% decrease - simplywall.st
Corvus Pharmaceuticals to announce atopic dermatitis trial results in January - Investing.com
Corvus Pharmaceuticals Confirms Plans to Announce Results - GlobeNewswire
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5%Should You Sell? - MarketBeat
Is Corvus Pharmaceuticals Inc a good long term investmentInsider Trading Activity & Free Real-Time Trading Signals - earlytimes.in
How strong is Corvus Pharmaceuticals Inc. stock balance sheetRetail Trading Trends & Free Trading Signals to Sharpen Your Edge - bollywoodhelpline.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5% – Still a Buy? - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5%Here's Why - MarketBeat
Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) added to S&P Biotechnology Select Industry Index - MarketScreener
IPO Launch: Will Corvus Pharmaceuticals Inc. stock split attract more investors2025 Earnings Surprises & Reliable Intraday Trade Plans - moha.gov.vn
Aug Macro: Why Corvus Pharmaceuticals Inc. stock appeals to dividend seekersJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - Улправда
Hedge Fund Moves: How strong is Corvus Pharmaceuticals Inc. stock balance sheet2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
- Улправда
Can Corvus Pharmaceuticals Inc. stock reach $100 price target2025 Key Highlights & Verified Swing Trading Watchlist - Улправда
Corvus Pharmaceuticals Earnings Notes - Trefis
Corvus Pharmaceuticals stock awaits key January 2026 trial data By Investing.com - Investing.com Canada
What is Corvus Pharmaceuticals Inc (CRVS) Stock Return on Shareholders’ Capital? - setenews.com
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% HigherWhat's Next? - MarketBeat
Corvus Pharmaceuticals Reports Promising Phase 1 Data for Soquelitinib in Relapsed/Refractory T Cell Lymphoma at ASH Annual Meeting - Quiver Quantitative
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial - The Manila Times
Corvus Pharma (CRVS) Stock Analysis Report | Financials & Insights - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month HighHere's What Happened - MarketBeat
You might want to take a look at Corvus Pharmaceuticals Inc (CRVS) now - setenews.com
Will Corvus Pharmaceuticals Inc. stock split again soonMarket Performance Report & Growth Focused Investment Plans - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8%Here's What Happened - MarketBeat
Here's Why We're Not Too Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation - Yahoo Finance
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):